Оксиконазол;
Тербинафин;
Эконазол.
Альтернативные ЛС (схемы лечения):
Итраконазол по 200—400 мг 3—7 сут; Кетоконазол по 200 мг 5—10 сут; Флуконазол по 400 мг однократно.
Литература
1.Климко Н.Н, Васильева Н.В., Елинов Н.П. и др. Перечень основных методов и критериев диагностики микозов. — Ñ-Ïá ÌÀÏÎ, 2001, 24 ñ.
2.Ajello L., Hay R.J. (eds). Medical mycology. Vol. 4 of Topley & Wilson’s Microbiology and microbial infections. London: Arnold, 1998.
3.Anaissie E.J., McGinnis M.R., Pfaller M.A. Clinical mycology. New York, Edinburgh, London, Philadelphia: Churchill Livingstone, 2002.
4.Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and American Society of Blood and Marrow transplantation. Morb Mort Wkly Rep 2000; 49 (RR-10):1—128.
5.Chapman S.W., Bradsher R.W., Campbell G.D. et al. Practice guidelines for the management of patient with blastomycosis. Clin Infect Dis 2000; 30:679—83.
6.Edwards J.E., Jr., Bodey G.P., Bowden R.A., et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25:43—59.
7.Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066— 72.
8.Fisher F., Cook N. Fundamentals of Diagnostic Mycology. Philadelphia: W.B. Saunders Company, 1998.
9.Galgiani J.N., Ampel N.M., Catanzaro A., et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30:658—61.
10.Groll A.H., Walsh T.J. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 (Supplement 2):8—24.
11.Hay R. Dermatophytosis and other superficial mycoses. In: Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. Fifth edn. Churchill Livingstone, 2000.
12.Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 Guidelines for the use of the antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730—51.
13.Kauffman C.A., Hajjeh R., Chapman S.W., et al. Practice guidelines for the management of patient with sporotrichosis. Clin Infect Dis 2000; 30: 684—7.
14.Kibbler C.C., Mackenzie D.W.R., Odds F.C. Principles and practice of clinical mycology. Chichester, New York: John Wiley & Sons, 1996.
15.Kontoyiannis D.P., Bodey G.P., Mantzoros C.S. Fluconazole vs. amphotericin B for the management of candidemia in adults: a me- ta-analysis. Mycoses. 2001; 44(5):125—35.
16.Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662—78.
17.Richardson M.D., Kokki M. Therapeutic guidelines in systemic fungal infections. 2nd edn. London: Current Medical Literature, 2001.
18.Saag M.A., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2000; 30:710—8.
19.Stevens D.A., Kan V.L., Judson M.A., et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30:676—709.
20.Sugar A. Agents of mucormycosis and related species. In: Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. Fifth edn. Churchill Livingstone, 2000.
21.Sugar A., Lyman C.A. A practical guide to medically important fungi and diseases they cause. Hagerstown: Lippincott-Raven Publishers, 1997.
22.Sutton D.A., Fothergill A.W., Rinaldi M.G. Guide to clinically significant fungi. Baltimore: Williams & Wilkins, 1998.
